These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 32638116)

  • 1. Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) at baseline of treatment in thalassemia patients: a referral center study.
    Safarnezhad Tameshkel F; Karbalaie Niya MH; Zamani F; Motamed N; Ajdarkosh H; Vafaeimanesh J; Khoonsari M; Sohrabi MR; Aten S; Azarkeivan A; Eslami MS; Perumal D; Maadi M; Ghanbari B; Keyvani H
    Arch Virol; 2020 Oct; 165(10):2193-2203. PubMed ID: 32638116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil.
    Malta F; Gaspareto KV; Lisboa-Neto G; Carrilho FJ; Mendes-Correa MC; Pinho JRR
    BMC Infect Dis; 2017 Nov; 17(1):716. PubMed ID: 29132303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
    Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
    Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Baseline Resistance-Associated Substitutions on Thalassemia Patients with Chronic HCV Infection: A Two-Year Follow-Up.
    Safarnezhad Tameshkel F; Karbalaie Niya MH; Khoonsari M; Ajdarkosh H; Faraji AH; Nikkhah M; Motamed N; Azarkeivan A; Gholami A; Sohrabi MR; Keyvani H; Zamani F
    Middle East J Dig Dis; 2021 Jan; 13(1):27-34. PubMed ID: 34712435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in iranian population.
    Ramezani A; Baesi K; Banifazl M; Mohraz M; Khorvash F; Yaran M; Tabarsi P; Dalirrooyfard AH; Motevalli F; Bavand A; Aghakhani A
    Clin Res Hepatol Gastroenterol; 2019 Oct; 43(5):594-602. PubMed ID: 31080115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.
    Di Maio VC; Cento V; Lenci I; Aragri M; Rossi P; Barbaliscia S; Melis M; Verucchi G; Magni CF; Teti E; Bertoli A; Antonucci F; Bellocchi MC; Micheli V; Masetti C; Landonio S; Francioso S; Santopaolo F; Pellicelli AM; Calvaruso V; Gianserra L; Siciliano M; Romagnoli D; Cozzolongo R; Grieco A; Vecchiet J; Morisco F; Merli M; Brancaccio G; Di Biagio A; Loggi E; Mastroianni CM; Pace Palitti V; Tarquini P; Puoti M; Taliani G; Sarmati L; Picciotto A; Vullo V; Caporaso N; Paoloni M; Pasquazzi C; Rizzardini G; Parruti G; Craxì A; Babudieri S; Andreoni M; Angelico M; Perno CF; Ceccherini-Silberstein F;
    Liver Int; 2017 Apr; 37(4):514-528. PubMed ID: 28105744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.
    Fahnøe U; Pedersen MS; Sølund C; Ernst A; Krarup HB; Røge BT; Christensen PB; Laursen AL; Gerstoft J; Thielsen P; Madsen LG; Pedersen AG; Schønning K; Weis N; Bukh J
    J Viral Hepat; 2021 Feb; 28(2):302-316. PubMed ID: 33131178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection.
    Esposito I; Marciano S; Haddad L; Galdame O; Franco A; Gadano A; Flichman D; Trinks J
    Viruses; 2018 Dec; 11(1):. PubMed ID: 30577623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of hepatitis C virus for subtype determination and resistance-associated substitutions detection among Chinese voluntary blood donors.
    Jiang X; Lv X; Chang L; Yan Y; Ji H; Sun H; Guo F; Rodgers MA; Yin P; Wang L
    Antiviral Res; 2020 Sep; 181():104871. PubMed ID: 32717286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Naturally Occurring Resistance-Associated Substitutions Between 2008 and 2016 in Chinese Patients with Chronic Hepatitis C Virus Infection.
    Huang W; Wang M; Gong Q; Yu D; Chen P; Lin J; Han Y; Su Y; Qu L; Zhang X
    Microb Drug Resist; 2019; 25(6):944-950. PubMed ID: 30702389
    [No Abstract]   [Full Text] [Related]  

  • 11. Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing.
    Nguyen T; Akhavan S; Caby F; Bonyhay L; Larrouy L; Gervais A; Lebray P; Poynard T; Calmus Y; Simon A; Valantin MA; Calvez V; Marcelin AG; Todesco E
    Int J Antimicrob Agents; 2019 Jan; 53(1):80-83. PubMed ID: 30236959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1.
    Costa VD; Delvaux N; Brandão-Mello CE; Nunes EP; de Sousa PSF; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC
    Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):700-706. PubMed ID: 30880098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report.
    Aldunate F; Echeverría N; Chiodi D; López P; Sánchez-Cicerón A; Soñora M; Cristina J; Moratorio G; Hernández N; Moreno P
    BMC Infect Dis; 2021 Apr; 21(1):387. PubMed ID: 33902462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance-associated substitutions in naïve patients from Argentina.
    Martínez AP; García G; Ridruejo E; Culasso AC; Pérez PS; Pereson MJ; Neukam K; Flichman D; Di Lello FA
    J Med Virol; 2019 Nov; 91(11):1970-1978. PubMed ID: 31273794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients.
    Aldunate F; Echeverría N; Chiodi D; López P; Sánchez-Cicerón A; Fajardo A; Soñora M; Cristina J; Hernández N; Moreno P
    Dis Markers; 2018; 2018():2514901. PubMed ID: 30186532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
    Dietz J; Müllhaupt B; Buggisch P; Graf C; Peiffer KH; Matschenz K; Schattenberg JM; Antoni C; Mauss S; Niederau C; Discher T; Trauth J; Dultz G; Schulze Zur Wiesch J; Piecha F; Klinker H; Müller T; Berg T; Neumann-Haefelin C; Berg CP; Zeuzem S; Sarrazin C; ; ; ;
    J Hepatol; 2023 Jan; 78(1):57-66. PubMed ID: 36031158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes.
    Costa VD; Brandão-Mello CE; Nunes EP; Dos Santos Silva PGC; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC
    PLoS One; 2019; 14(5):e0216327. PubMed ID: 31063475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance-associated variants in HCV subtypes 1a and 1b detected by Ion Torrent sequencing platform.
    Gaspareto KV; Ribeiro RM; de Mello Malta F; Gomes-Gouvêa MS; Muto NH; Romano CM; Mendes-Correa MC; Carrilho FJ; Sabino EC; Rebello Pinho JR
    Antivir Ther; 2016; 21(8):653-660. PubMed ID: 27314166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.
    Paolucci S; Fiorina L; Mariani B; Gulminetti R; Novati S; Barbarini G; Bruno R; Baldanti F
    Virol J; 2013 Dec; 10():355. PubMed ID: 24341898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection.
    Dietz J; Kalinina OV; Vermehren J; Peiffer KH; Matschenz K; Buggisch P; Niederau C; Schattenberg JM; Müllhaupt B; Yerly S; Ringelhan M; Schmid RM; Antoni C; Müller T; Schulze Zur Wiesch J; Piecha F; Moradpour D; Deterding K; Wedemeyer H; Moreno C; Berg T; Berg CP; Zeuzem S; Welsch C; Sarrazin C;
    J Viral Hepat; 2020 Oct; 27(10):974-986. PubMed ID: 32396998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.